Transcarent, a leading consumer-driven healthcare platform, has completed its acquisition of Accolade for US$621 million, creating one of the most comprehensive health and care platforms for employers and health plans. The deal was announced on January 8, 2025, and closed on April 8, 2025, following regulatory and shareholder approvals.

The combined organization now serves over 20 million members and 1,700 employer and health plan clients, offering a unified platform that integrates Transcarent’s digital-first, AI-powered WayFinding and Care Experiences with Accolade’s strengths in health advocacy, expert medical opinions, and virtual primary care.

Glen Tullman continues as CEO, with Snezana Mahon, Pharm.D. promoted to President. Legal counsel was provided by Wilson Sonsini, BLG, and Cooley LLP, with financing led by General Catalyst, 62 Ventures, and others. Accolade is now privately held and delisted from Nasdaq.